Stock Scorecard



Stock Summary for Design Therapeutics Inc (DSGN) - $4.87 as of 1/22/2025 8:41:01 AM EST

Total Score

9 out of 30

Safety Score

23 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for DSGN

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for DSGN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for DSGN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for DSGN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for DSGN (23 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 2
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0

Latest News for for DSGN

Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Dave ( NASDAQ:DAVE ) , ARKO ( NASDAQ:ARKO ) 12/31/2024 1:47:00 PM
Why Cemtrex Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket - Alset ( NASDAQ:AEI ) , Ambow Education Holding ( AMEX:AMBO ) 12/31/2024 10:33:00 AM
MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Cullinan Therapeutics ( NASDAQ:CGEM ) 12/26/2024 1:49:00 PM
Lamb Weston Posts Weak Q2 Results, Joins Micron, Lennar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Akso Health ( NASDAQ:AHG ) , Abacus Life ( NASDAQ:ABL ) 12/19/2024 1:29:00 PM
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Aethlon Medical ( NASDAQ:AEMD ) , Abacus Life ( NASDAQ:ABL ) 12/19/2024 11:15:00 AM
NVIDIA Opens BioNeMo to Scale Digital Biology for Global Biopharma and Scientific Industry - NVIDIA ( NASDAQ:NVDA ) 11/18/2024 6:30:00 PM
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences - Design Therapeutics ( NASDAQ:DSGN ) 11/13/2024 1:00:00 PM
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences 11/13/2024 1:00:00 PM
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference - Design Therapeutics ( NASDAQ:DSGN ) 9/10/2024 12:00:00 PM
Palatin Technologies: Utilizing The Melanocortin System As The Basis For Innovation In Drug Development - Targeting Inflammatory & Autoimmune Conditions, Obesity And Sexual Dysfunctions - Palatin Techs ( AMEX:PTN ) 8/28/2024 12:54:00 PM

Financial Details for DSGN

Company Overview

Ticker DSGN
Company Name Design Therapeutics Inc
Country USA
Description Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company is headquartered in Carlsbad, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date 3/17/2025

Stock Price History

Last Day Price 4.87
Price 4 Years Ago 21.41
Last Day Price Updated 1/22/2025 8:41:01 AM EST
Last Day Volume 228,727
Average Daily Volume 220,054
52-Week High 7.77
52-Week Low 2.25
Last Price to 52 Week Low 116.44%

Valuation Measures

Trailing PE N/A
Industry PE 21.55
Sector PE 41.24
5-Year Average PE -11.44
Free Cash Flow Ratio 1.08
Industry Free Cash Flow Ratio 11.72
Sector Free Cash Flow Ratio 27.18
Current Ratio Most Recent Quarter 34.61
Total Cash Per Share 4.49
Book Value Per Share Most Recent Quarter 4.46
Price to Book Ratio 1.14
Industry Price to Book Ratio 4.84
Sector Price to Book Ratio 20.52
Price to Sales Ratio Twelve Trailing Months 22,642.01
Industry Price to Sales Ratio Twelve Trailing Months 81.24
Sector Price to Sales Ratio Twelve Trailing Months 24.40
Analyst Buy Ratings 0
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 56,621,000
Market Capitalization 275,744,270
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -5.61%
Reported EPS 12 Trailing Months -0.85
Reported EPS Past Year -0.64
Reported EPS Prior Year -1.20
Net Income Twelve Trailing Months -47,779,000
Net Income Past Year -66,862,000
Net Income Prior Year -63,308,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth -72.90%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 254,100,000
Total Cash Past Year 281,800,000
Total Cash Prior Year 330,400,000
Net Cash Position Most Recent Quarter 254,100,000
Net Cash Position Past Year 281,800,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 277,687,000
Total Stockholder Equity Prior Year 327,310,000
Total Stockholder Equity Most Recent Quarter 252,453,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -46,410,000
Free Cash Flow Per Share Twelve Trailing Months -0.82
Free Cash Flow Past Year -58,816,000
Free Cash Flow Prior Year -52,235,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.43
MACD Signal -0.23
20-Day Bollinger Lower Band 4.46
20-Day Bollinger Middle Band 5.58
20-Day Bollinger Upper Band 6.70
Beta 1.83
RSI 40.83
50-Day SMA 4.47
150-Day SMA 7.98
200-Day SMA 0.00

System

Modified 1/20/2025 11:09:57 PM EST